Advancing Breakthrough Therapies for Cancer
Seattle Genetics is a biotechnology company focused on developing and commercializing innovative, empowered antibody-based therapies for the treatment of cancer. We are the industry leader in antibody-drug conjugates (ADCs), a technology designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. ADCs are intended to spare non-targeted cells and thus reduce many of the toxic effects of traditional chemotherapy, while potentially enhancing antitumor activity.
First in a New Class of ADCs
The company’s first ADC product ADCETRIS® (brentuximab vedotin) received accelerated approval from the U.S. Food and Drug Administration in August 2011 and approval with conditions from Health Canada in February 2013 for relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma, an aggressive type of T-cell non-Hodgkin lymphoma. Additionally, the European Commission granted Millennium conditional marketing authorization in October 2012. The approval of ADCETRIS makes it the first in a new class of ADCs.
To expand on the ADCETRIS opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in earlier lines of its approved indications as well as in a range of other lymphoma and non-lymphoma settings.
Seattle Genetics is jointly developing ADCETRIS in collaboration with Takeda Pharmaceutical Company Limited and Millennium: The Takeda Oncology Company. Under the collaboration, Seattle Genetics has full commercialization rights to ADCETRIS in the United States and Canada. Millennium has exclusive rights to commercialize the product candidate in all other countries.
Advancing Our Robust ADC Pipeline
In addition to ADCETRIS, we are advancing a robust ADC product pipeline designed to address the unmet medical needs of people with cancer. We have robust research and development capabilities that are our engine for innovation and long-term growth. Our ADC technology is also employed by collaborators, who combined are advancing more than 15 programs in clinical development using Seattle Genetics' proprietary approach to empowering antibodies.
Seattle Genetics was founded in 1998 and is headquartered in Bothell, Washington, a suburb of Seattle. The company completed an initial public offering in March 2001, and is traded on the Nasdaq Stock Market under the symbol SGEN. We have more than 500 employees throughout the United States, all with a passion for helping people living with cancer.